Eli Lilly's Ebglyss Receives FDA Approval for Every-8-Week Maintenance Dosing in Atopic Dermatitis

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) with an extended maintenance treatment interval of every 8 weeks, the company announced. The approval covers adults and adolescents aged 12 and older with moderate-to-severe atopic dermatitis (eczema) weighing at least 88 pounds (approximately 40 kilograms).
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments